Abstract
Ischemic stroke is a leading cause of morbidity and mortality worldwide which incidence is increasing with society aging. Unfortunately, despite intensive research in treatments to reduce mortality and the severity of the cerebrovascular injury, there are not effective therapies available. Hypoxia-Inducible Factor-1 (HIF-1) triggers the overexpression of genes coding for proteins involved in the adaptative response of the cell to oxygen deprivation. The functional HIF unit is a heterodimeric protein composed of the two subunits, HIF-1alpha and HIF-1beta. HIF-1alpha activity is regulated through different mechanisms involving post-transcriptional and post-translational modifications. During normoxia, prolyl hydroxylases modify HIF-1alpha and marks it for proteasomal degradation. Under hypoxia, reduced activity of prolyl hydroxylases allows stabilization of HIF-1alpha and increases protein levels. Also, several transduction pathways have been proposed to act downstream of putative oxygen sensors and lead to HIF-1alpha phosphorylation by kinases. Collectively, these modifications regulate HIF-1alpha activity inducing gene expression associated with brain protection after ischemia. In this review, we summarize some of the latest compounds that have shown to regulate HIF function and induce protection in brain cells subjected to ischemia. We focus on compounds that target HIF hydroxylases and the PI-3K/Akt and the MAPK/ERK pathways. Increased HIF-1alpha expression holds great promise for the treatment of cerebral ischemia and makes HIF hydroxylases and kinases attractive therapeutic targets. The reduced number of reports associated to the study of kinases and HIF-1alpha in brain, points out the need of further investigation.
Keywords: Cerebral ischemia, HIF-1alpha, MAPK/ERK, PI-3K/Akt, prolyl hydroxylases inhibitors, brain ischemia, Hypoxia-Inducible Factor-1 (HIF-1a), prolyl hydroxylases (PH), phosphoinositide 3-kinase (PI-3k), mitogen activated protein kinases (MAPK), Prolil hydroxylation inhibition, Asparaginil hydroxylation inhibition, TM6008, TM6089, Ethyl 3,4-dihydroxybenzoato (EDHB), Deferoxamine (DFO), Metal Ions, Cobalt chloride (CoCl2), Ginkgolides, Baicalein, Clioquinol, Zinc, Erytrhopoietin, hypoxia, HIF-1 phosphorylation, PH inhibitors, Tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN), MCAO, chemical hypoxia, ischemic stroke
Current Signal Transduction Therapy
Title: Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Volume: 6 Issue: 2
Author(s): Maria Elena Chanez-Cardenas, Monica Espinoza-Rojo, Jose A. Rivera-Rodriguez and Penelope Aguilera
Affiliation:
Keywords: Cerebral ischemia, HIF-1alpha, MAPK/ERK, PI-3K/Akt, prolyl hydroxylases inhibitors, brain ischemia, Hypoxia-Inducible Factor-1 (HIF-1a), prolyl hydroxylases (PH), phosphoinositide 3-kinase (PI-3k), mitogen activated protein kinases (MAPK), Prolil hydroxylation inhibition, Asparaginil hydroxylation inhibition, TM6008, TM6089, Ethyl 3,4-dihydroxybenzoato (EDHB), Deferoxamine (DFO), Metal Ions, Cobalt chloride (CoCl2), Ginkgolides, Baicalein, Clioquinol, Zinc, Erytrhopoietin, hypoxia, HIF-1 phosphorylation, PH inhibitors, Tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN), MCAO, chemical hypoxia, ischemic stroke
Abstract: Ischemic stroke is a leading cause of morbidity and mortality worldwide which incidence is increasing with society aging. Unfortunately, despite intensive research in treatments to reduce mortality and the severity of the cerebrovascular injury, there are not effective therapies available. Hypoxia-Inducible Factor-1 (HIF-1) triggers the overexpression of genes coding for proteins involved in the adaptative response of the cell to oxygen deprivation. The functional HIF unit is a heterodimeric protein composed of the two subunits, HIF-1alpha and HIF-1beta. HIF-1alpha activity is regulated through different mechanisms involving post-transcriptional and post-translational modifications. During normoxia, prolyl hydroxylases modify HIF-1alpha and marks it for proteasomal degradation. Under hypoxia, reduced activity of prolyl hydroxylases allows stabilization of HIF-1alpha and increases protein levels. Also, several transduction pathways have been proposed to act downstream of putative oxygen sensors and lead to HIF-1alpha phosphorylation by kinases. Collectively, these modifications regulate HIF-1alpha activity inducing gene expression associated with brain protection after ischemia. In this review, we summarize some of the latest compounds that have shown to regulate HIF function and induce protection in brain cells subjected to ischemia. We focus on compounds that target HIF hydroxylases and the PI-3K/Akt and the MAPK/ERK pathways. Increased HIF-1alpha expression holds great promise for the treatment of cerebral ischemia and makes HIF hydroxylases and kinases attractive therapeutic targets. The reduced number of reports associated to the study of kinases and HIF-1alpha in brain, points out the need of further investigation.
Export Options
About this article
Cite this article as:
Elena Chanez-Cardenas Maria, Espinoza-Rojo Monica, A. Rivera-Rodriguez Jose and Aguilera Penelope, Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795660061
DOI https://dx.doi.org/10.2174/157436211795660061 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Editorial [Hot Topic: SOD Enzymes and Their Mimics in Cancer: Pro- vs Anti-Oxidative Mode of Action-Part I (Guest Editor: Ines Batinic-Haberle)]
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews Correlation between Potassium Channel Expression and Sensitivity to Drug-induced Cell Death in Tumor Cell Lines
Current Pharmaceutical Design Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry